CPX-571 Improves Anti-Tumor Activity
Celator Pharmaceuticals announced positive results from preclinical studies to evaluate the optimal ratio of irinotecan and cisplatin to deliver synergistic benefit against a range of tumor cell lines in vitro.
The study further worked to develop an effective formulation to maintain the optimal ratio of these drugs in vivo. Results were presented this week in a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.
In the study, combinations of irinotecan and cisplatin were applied to a panel of 20 human and murine tumor cell lines enriched with lung tumor carcinomas in vitro to identify the ratios most likely to deliver synergistic benefit. The combination exhibited strong drug ratio dependent synergy. Using Celator's proprietary CombiPlex technology, researchers then engineered a combination of irinotecan and cisplatin in liposomes to maintain a synergistic 7:1 molar ratio following intravenous administration. The product, known as CPX-571, was compared to a combination of irinotecan and cisplatin administered as free drugs, and to monotherapy with each drug agent administered in a liposome formulation in